Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
AIDS Res Hum Retroviruses ; 33(4): 386-394, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-27819156

RESUMO

Antiretroviral therapy (ART) can be compromised by selection of drug resistance strains, which can be promoted by lack of adherence during therapy and drug tolerance, and some of these drug-resistant strains can persist for years as minority populations. The K103N drug resistance mutation is selected by the use of non-nucleotide reverse transcriptase inhibitors, including nevirapine or efavirenz (EFV), used in low-income countries. Here we describe the use of a less expensive qualitative point mutation polymerase chain reaction (PMqPCRK103N) targeting K103N mutation. To validate the use of this methodology, we tested previously sequenced samples from patients treated with highly active ART with viral loads above 2,000 copies/ml and compared the results of our assay with Illumina deep sequencing. Due to its low cost and high specificity, this test is particularly suitable for low-income countries to screen for pretreatment resistance in patients either initiating ART or failing first-line regimens containing EFV.


Assuntos
Monitoramento de Medicamentos/métodos , Farmacorresistência Viral , Infecções por HIV/diagnóstico , Infecções por HIV/tratamento farmacológico , Reação em Cadeia da Polimerase/métodos , Inibidores da Transcriptase Reversa/uso terapêutico , Alcinos , Benzoxazinas/uso terapêutico , Custos e Análise de Custo , Ciclopropanos , Monitoramento de Medicamentos/economia , Técnicas de Genotipagem/economia , Técnicas de Genotipagem/métodos , Infecções por HIV/virologia , Humanos , Mutação de Sentido Incorreto , Nevirapina/uso terapêutico , Mutação Puntual , Reação em Cadeia da Polimerase/economia , Sensibilidade e Especificidade , Falha de Tratamento
2.
Genet Mol Biol ; 37(1): 120-6, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24688299

RESUMO

Engineered nucleases such as zinc finger nucleases (ZFN) and transcription activator-like effector nucleases (TALEN) are one of the most promising tools for modifying genomes. These site-specific enzymes cause double-strand breaks that allow gene disruption or gene insertion, thereby facilitating genetic manipulation. The major problem associated with this approach is the labor-intensive procedures required to screen and confirm the cellular modification by nucleases. In this work, we produced a TALEN that targets the human CCR5 gene and developed a heteroduplex mobility assay for HEK 293T cells to select positive colonies for sequencing. This approach provides a useful tool for the quick detection and easy assessment of nuclease activity.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA